NaranjoCABustoUSellersEMSandorPRuizIRobertsEAA method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981;30:239–45.
2.
KirchWJanischHDSantosSRDuhrsenUDylewiczPOhnhausEE. Effect of cisapride and metoclopramide on digoxin bioavailability. Eur J Drug Metab Pharmacokinet1986;11:249–50.
3.
ManninenVApajalahtiAMelinJKaresojaM. Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet1973;1:398–400.
4.
Product information (Australian approved). Lanoxin (digoxin). Melbourne, Australia: Sigma Pharmaceuticals Pty., Ltd. Last amended May 28, 1998.
5.
JohnsonBFBustrackJUrbachDHeyward-HullJMarwahaR. Effect of metoclopramide on digoxin absorption from tablets and capsules. Clin Pharm Ther1984;36:724–30.
6.
BedfordTARowbothamDJ. Cisapride — Drug interactions of clinical significance. Drug Saf1996;15:167–75.
7.
BeermanBHellstromKRosenA. The absorption of orally administered digoxin in man. Clin Sci1972;43:507–18.
8.
RodinSMJohnsonBF. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet1988;15:227–44.
9.
LindenbaumJRundDGButlerVPTse-EngDSahaJN. Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. N Engl J Med1981;305:789–94.
10.
BrownDDSpectorRJuhlRP. Drug interactions with digoxin. Drugs1980;20:198–206.
11.
WoodlandCItoSKorenG. A model for the prediction of digoxin– Drug interactions at the renal tubular cell level. Ther Drug Monit1998;20:134–8.
12.
WisemanLRFauldsD. Cisapride: An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs1994;47:116–52.
